Helix BioPharma Corp. (HBPCF)
Helix BioPharma Corp. is a Canadian enterprise focused on immuno-oncology. The company's research and development efforts include L-DOS47, a drug candidate aimed at treating non-small cell lung cancer, and V-DOS47, which is designed to interact with vascular epithelial growth factor receptor 2 (VEGFR2). Helix has established collaborative agreements to further its research. One such partnership with Moffitt Cancer Center involves studying L-DOS47's pharmacodynamics and exploring the advantages of co-administering it with immune checkpoint inhibitors. A separate collaboration with University Hospital Tuebingen focuses on evaluating L-DOS47's therapeutic impact on CEACAM6-positive cancer models, employing advanced preclinical metabolic imaging techniques. The company's corporate headquarters are located in Toronto, Canada.
Sector: Biotechnology
Industry: Biotechnology
Helix BioPharma Corp.
- Not computed yet: no FINRA short interest has been matched to this float.
- 5
- 1.00
Float 46.72M · FMP free float
The cost to borrow HBPCF shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- No fails on record for 16–31 Oct 2026.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Mar 31, 2026 | 5 sh |
| Mar 13, 2026 | 5 sh |
| Feb 27, 2026 | 5 sh |
| Feb 13, 2026 | 5 sh |
| Jan 30, 2026 | 5 sh |
A stock split executed inside this window; every settlement plotted has been carried onto today’s share basis, so the line does not step at the split.
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
Too few published sessions to show a reading in context.
FINRA's weekly alternative trading system (dark pool) volume for HBPCF: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.